X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3035) 3035
Newsletter (111) 111
Newspaper Article (77) 77
Book Chapter (12) 12
Magazine Article (5) 5
Dissertation (3) 3
Transcript (3) 3
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
crizotinib (2965) 2965
oncology (1540) 1540
humans (1433) 1433
chemotherapy (929) 929
lung cancer (852) 852
cancer (790) 790
lung cancer, non-small cell (734) 734
lung neoplasms - drug therapy (709) 709
anaplastic lymphoma kinase (692) 692
female (691) 691
mutation (657) 657
lung neoplasms - genetics (635) 635
male (631) 631
alk (610) 610
carcinoma, non-small-cell lung - drug therapy (587) 587
middle aged (537) 537
lymphomas (503) 503
carcinoma, non-small-cell lung - genetics (485) 485
respiratory system (471) 471
lung neoplasms - pathology (461) 461
protein kinase inhibitors - therapeutic use (444) 444
adult (441) 441
cell lung-cancer (440) 440
open-label (432) 432
non-small cell lung cancer (431) 431
research (427) 427
adenocarcinoma (421) 421
aged (421) 421
receptor protein-tyrosine kinases - genetics (411) 411
care and treatment (384) 384
resistance (370) 370
metastasis (355) 355
antineoplastic agents - therapeutic use (340) 340
alectinib (328) 328
kinases (328) 328
tumors (326) 326
carcinoma, non-small-cell lung - pathology (323) 323
mutations (309) 309
nsclc (309) 309
ceritinib (308) 308
pyridines - therapeutic use (298) 298
gene rearrangement (290) 290
genetic aspects (290) 290
pyrazoles - therapeutic use (290) 290
patients (284) 284
immunohistochemistry (270) 270
egfr (269) 269
cancer therapies (265) 265
hemic and lymphatic diseases (254) 254
protein kinase inhibitors - pharmacology (254) 254
animals (252) 252
receptor protein-tyrosine kinases - antagonists & inhibitors (251) 251
analysis (247) 247
gene (242) 242
tyrosine (240) 240
non-small cell lung carcinoma (234) 234
acquired-resistance (230) 230
gefitinib (228) 228
identification (221) 221
aged, 80 and over (220) 220
pharmacology & pharmacy (219) 219
cell line, tumor (214) 214
inhibitor (213) 213
protein-tyrosine kinase (209) 209
treatment outcome (207) 207
lung cancer, small cell (203) 203
drug therapy (202) 202
health aspects (199) 199
prognosis (198) 198
inhibitors (194) 194
therapy (191) 191
physical fitness (189) 189
targeted therapy (189) 189
survival (188) 188
lymphoma (187) 187
oncogene proteins, fusion - genetics (184) 184
receptor protein-tyrosine kinases - metabolism (182) 182
eml4-alk fusion gene (178) 178
ros1 (177) 177
adenocarcinoma - genetics (175) 175
antineoplastic agents - pharmacology (174) 174
crizotinib resistance (170) 170
non-small-cell lung cancer (168) 168
oncology, experimental (168) 168
c-met (164) 164
neoplasms. tumors. oncology. including cancer and carcinogens (162) 162
pyridines - pharmacology (156) 156
pathology (155) 155
expression (153) 153
pyrazoles - pharmacology (149) 149
safety (148) 148
eml4-alk (145) 145
erlotinib (145) 145
lung neoplasms - enzymology (145) 145
lung-cancer (145) 145
hematology, oncology and palliative medicine (144) 144
molecular targeted therapy (144) 144
development and progression (143) 143
neoplasm staging (143) 143
brain metastases (140) 140
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3161) 3161
French (55) 55
Chinese (26) 26
German (19) 19
Japanese (10) 10
Portuguese (4) 4
Czech (3) 3
Russian (3) 3
Spanish (2) 2
Korean (1) 1
Polish (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer discovery, ISSN 2159-8290, 2018, Volume 8, Issue 6, pp. 714 - 729
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 12, pp. 1199 - 1206
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 11/2019, Volume 20, Issue 22, p. 5590
Several promising anti-cancer drug-GnRH (gonadotropin-releasing hormone) conjugates have been developed in the last two decades, although none of them have... 
permeability 4 | targeted drug delivery 1 | HORMONE RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | KINASE INHIBITORS | lysosome 3 | endocytosis 9 | CANCER | CHEMISTRY, MULTIDISCIPLINARY | PEPTIDE | crizotinib 5 | TARGETED CYTOTOXIC ANALOG | LHRH | IN-VITRO | GnRH 2 | galectin 10 | c-Met 8 | NSCLC 7 | conjugate 6 | GnRHR 3 | EXPRESSION | MEMBRANE PERMEABILIZATION | Proto-Oncogene Proteins c-met - metabolism | Skin - cytology | Humans | Lung Neoplasms - metabolism | Gonadotropin-Releasing Hormone - pharmacology | Lung Neoplasms - pathology | Drug Delivery Systems | Lysosomes - metabolism | Gonadotropin-Releasing Hormone - chemistry | Drug Design | Receptors, LHRH - metabolism | Crizotinib - chemical synthesis | Gonadotropin-Releasing Hormone - chemical synthesis | Fibroblasts - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - metabolism | Crizotinib - chemistry | Models, Biological | Cell Membrane Permeability - drug effects | Crizotinib - pharmacology | Cell Line, Tumor | Galectins - metabolism | Hydrogen-Ion Concentration | Cell culture | Conjugates | Drug delivery systems | Epidermal growth factor receptors | Drug delivery | Selectivity | Kinases | Enantiomers | High-performance liquid chromatography | Signal transduction | Side effects | Epidermal growth factor | Inhibitors | Acids | Fibroblasts | Gonadotropin-releasing hormone | Prostate | Growth factors | Cancer | gnrhr 3 | c-met 8 | gnrh 2 | nsclc 7
Journal Article
Journal of translational medicine, ISSN 1479-5876, 2019, Volume 17, Issue 1, pp. 52 - 9
BackgroundMET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors... 
Crizotinib | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | GEFITINIB | Lung cancer | ADENOCARCINOMA | ASIAN PATIENTS | OPEN-LABEL | Survival | EGFR | Resistance | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | C-MET | MET amplification | MUTATIONS | Proto-Oncogene Proteins c-met - metabolism | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Tomography, X-Ray Computed | Protein Kinase Inhibitors - adverse effects | Treatment Failure | Female | Retrospective Studies | Lung Neoplasms - genetics | Crizotinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Mutation - genetics | Crizotinib - adverse effects | Disease Progression | Proto-Oncogene Proteins c-met - genetics | Disease-Free Survival | Gene Amplification | Protein Kinase Inhibitors - therapeutic use | Crizotinib - pharmacology | Lung Neoplasms - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Epidermal growth factor | Analysis | Fluorescence | Health aspects | Chromosomes | Liver | Hybridization | Kinases | Drug resistance | Cancer therapies | c-Met protein | Signal transduction | Fluorescence in situ hybridization | MET protein | Growth factors | Drug dosages | Protein-tyrosine kinase | Effectiveness | Epidermal growth factor receptors | Medical treatment | Non-small cell lung carcinoma | Nausea | Disease control | Patients | Amplification | Gene amplification | Chemotherapy | Medical prognosis | Response rates | Mutation
Journal Article
Cancer cell, ISSN 1535-6108, 2014, Volume 26, Issue 5, pp. 682 - 694
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 11/2019, Volume 25, Issue 22, pp. 6671 - 6682
Purpose: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) inevitably develop resistance to ALK inhibitors. New... 
CRIZOTINIB | MECHANISMS | LIQUID BIOPSIES | ALIGNMENT | ONCOLOGY | COPY NUMBER
Journal Article
Clinical cancer research, ISSN 1557-3265, 2014, Volume 20, Issue 22, pp. 5686 - 5696
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non-small cell lung cancer... 
CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | NVP-TAE684 | ONCOLOGY | CERITINIB | EML4-ALK FUSION GENE | SENSITIVITY | CH5424802 | CRIZOTINIB RESISTANCE | NEUROBLASTOMA | IDENTIFICATION | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Lung Neoplasms - metabolism | Tomography, X-Ray Computed | Dose-Response Relationship, Drug | Piperidines - pharmacology | DNA Mutational Analysis | Inhibitory Concentration 50 | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Models, Molecular | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Protein Conformation | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carbazoles - pharmacology | Receptor Protein-Tyrosine Kinases - chemistry | gatekeeper mutation | crizotinib | ALK-rearranged NSCLC | alectinib (RO5424802 | resistance | ceritinib (LDK378)
Journal Article